Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1233 | Exercise Group Wiki | 0.33 |
| drug1847 | Liver function tests ,serum ferritin and PCR for COVID-19 . Wiki | 0.33 |
| drug962 | D-dimer,CBC.ESR,CRP, Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3834 | chronic pain team Wiki | 0.33 |
| drug3064 | Self-Compassion for Chronic Pain Virtual Group Treatment Program Wiki | 0.33 |
| drug726 | Cannabis, Medical Wiki | 0.33 |
| drug1711 | Intervention program Wiki | 0.33 |
| drug976 | DUR-928 Wiki | 0.33 |
| drug582 | CAP-1002 Allogeneic Cardiosphere-Derived Cells Wiki | 0.33 |
| drug1235 | Exercise Testing and Training Wiki | 0.33 |
| drug956 | CytoSorb 300 mL device Wiki | 0.33 |
| drug957 | CytoSorb-Therapy Wiki | 0.33 |
| drug3383 | Tele-Yoga Therapy Wiki | 0.33 |
| drug3829 | chiropractic team Wiki | 0.33 |
| drug4071 | questionnaire assesment Wiki | 0.30 |
| drug963 | DAS181 Wiki | 0.27 |
| drug422 | BNT162b2 Wiki | 0.24 |
| drug421 | BNT162b1 Wiki | 0.19 |
| drug776 | Chloroquine Wiki | 0.13 |
| drug2557 | Placebo oral tablet Wiki | 0.06 |
| drug2505 | Placebo Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D059350 | Chronic Pain NIH | 0.90 |
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.33 |
| D005879 | Tourette Syndrome NIH | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000070642 | Brain Injuries, Traumatic NIH | 0.24 |
| D013122 | Spinal Diseases NIH | 0.24 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.24 |
| D000755 | Anemia, Sickle Cell NIH | 0.24 |
| D016472 | Motor Neuron Disease NIH | 0.24 |
| D001714 | Bipolar Disorder NIH | 0.24 |
| D001930 | Brain Injuries, NIH | 0.20 |
| D012640 | Seizures NIH | 0.19 |
| D005356 | Fibromyalgia NIH | 0.17 |
| D001927 | Brain Diseases NIH | 0.17 |
| D059352 | Musculoskeletal Pain NIH | 0.14 |
| D003095 | Collagen Diseases NIH | 0.14 |
| D010300 | Parkinsonian NIH | 0.13 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.13 |
| D012216 | Rheumatic Diseases NIH | 0.12 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.11 |
| D003424 | Crohn Disease NIH | 0.11 |
| D001172 | Arthritis, Rheumatoid NIH | 0.10 |
| D012598 | Scoliosi NIH | 0.09 |
| D009103 | Multiple Sclerosis NIH | 0.09 |
| D001168 | Arthritis NIH | 0.09 |
| D013577 | Syndrome NIH | 0.06 |
| D040921 | Stress Disorders, Traumatic NIH | 0.06 |
| D014947 | Wounds and Injuries NIH | 0.06 |
| D004194 | Disease NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.33 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.33 |
| HP:0100754 | Mania HPO | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001250 | Seizure HPO | 0.19 |
| HP:0001298 | Encephalopathy HPO | 0.17 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.13 |
| HP:0001370 | Rheumatoid arthritis HPO | 0.12 |
| HP:0100280 | Crohn's disease HPO | 0.11 |
| HP:0001369 | Arthritis HPO | 0.10 |
Navigate: Correlations HPO
There are 9 clinical trials
The wars in Iraq and Afghanistan are creating a new generation of Veterans, including an increasing number of women Veterans, who present with comorbid PTSD and chronic pain conditions from recent deployment-related physical injuries and exposure to psychological trauma. Health behavior change has become increasingly important in treating these conditions and proactively preventing long-term negative health sequelae, in order to benefit these Veterans directly and reduce the growing challenges to our healthcare system. The proposed CDA-2 program of research will use an innovative translational research approach to study whether a chronic progressive -based exercise program will reduce chronic pain in patients with PTSD and to elucidate and modify potential PTSD-related deficiencies in neurobiological and psychological responses to exercise to optimize the physical and psychological benefits of exercise for these individuals.
Description: To be administered at: Screening Evaluation & Endpoint 13 week exercise test sessions This 30-item structured interview is designed to assess both the 17 symptoms of PTSD and the 8 hypothesized associated features. The scale yields a dichotomous diagnosis of PTSD, and also provides a continuous score of frequency and severity for each symptom. In addition, a behaviorally anchored probe question is provided for each symptom to increase the reliability of administration. The CAPS-5 is currently in the process of being validated however its previous version demonstrated excellent sensitivity (.81) and specificity (.95).57
Measure: Change from Baseline: Clinician Administered PTSD Scale -5 Time: Baseline and endpoint (at 13 weeks)Description: The WHY-MPI has been demonstrated to be applicable across a variety of clinical pain conditions. Its brevity, validity/ reliability, self-report nature and ease of scoring make it ideal for both clinical and research purposes. The WHY-MPI is sensitive to change following rehabilitation. Please note only the interference subscale of the WHY-MPI will be administered in this study.
Measure: Change from Baseline: West Haven=Yale Multidimensional Pain Inventory- Interference Subscale (WHY-MPI) Time: Baseline, Midpoint (at 6 weeks) and Endpoint (at 13 weeks)This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsClinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.
Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.
Measure: self-reported questionnaire for painful Time: maximum 1 week from baseline onIn the context of quarantine with COVID-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. We will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation
The quarantine during COVID-19 pandemic has changed daily routine. Staying at home for prolonged periods of time can pose a significant challenge for patients with chronic pain. The purpose of the current study is to investigate how the quarantine effects of psychosocial factors, quality of life, sleep, nutrition and physical activity in patients with chronic musculoskeletal pain. Another purpose is to examine whether a telerehabilitation exercise program is effective during the lockdown period.
Description: To measure the levels of anxiety and depression Hospital Anxiety and Depression Scale (HADS), will be used. Patients have to score 14 opinions. Seven of the items relate to anxiety and seven relate to depression. A cut-off point of 8/21 for anxiety or depression has been recommended.
Measure: Anxiety and Depression Time: Change From Baseline in HADS at 40 daysDescription: To measure quality of life, EQ-5D-3L will be used. The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Measure: Quality of Life and overall health Time: Change From Baseline in EQ-5D-3L at 40 daysDescription: The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults and it will be used in the current study. The most commonly used is the 11-item NPRS. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").The NPRS is a valid and reliable scale to measure pain intensity. In this study, will rate current pain intensity and mean pain intensity during the past 7 days.
Measure: Pain Intensity Time: Change From Baseline in NPRS Scores at 40 daysDescription: The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in the older adult. PSQI will be used to assess quality and patterns of sleep in the current study. PSQI differentiates "poor" from "good" sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The client self-rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the client's bed mate or roommate, these are not scored, nor reflected in the attached instrument. An update to the scoring: if 5 is not complete or the value is missing, it now counts as a "0".
Measure: Quality and patterns of sleep Time: Change From Baseline in PSQI Scores at 40 daysDescription: Patients' illness perceptions will be measured based on the Brief Illness Perception Questionnaire (BIPQ). The patient has to rate 8 statements on a 10-point scale (1-10). The higher the score, the greater is the extent to which the patient's illness perceptions are threatening him or her.
Measure: Patients' illness perceptions Time: Change From Baseline in BIPQ Scores at 40 daysDescription: Disability will be assessed using Oswestry Disability Index (ODI) that present ten sections cover Pain, Personal Care, Lifting, Walking, Sitting, Standing, Sleeping, Sex Life, Social Life, and Traveling. Each section has six statements reflecting an increasing level of disability. Respondents choose the statement that most applies to them in each section. The first statement is scored 0; the second is scored 1 and so on to 5 for the last statement. The sum of the section scores is divided by 50 if all sections are completed and multiplied by 100 for the final percentage score.
Measure: Disability Time: Change From Baseline in ODI Scores at 40 daysCOVID-19 (coronavirus 2019) disease has led to a large number of hospital admissions, many of which require admission to intensive care (ICU). Post-intensive care syndrome (PICS) is defined as deterioration or worsening of previous deterioration in the mental, physical or cognitive status that appears as a consequence of a critical illness and which persists after acute hospital care. Also, there is evidence that patients who survive a critical illness have a high prevalence of moderate to extreme chronic pain. Patients with COVID-19 disease are an especially susceptible population to develop PICS due to acute respiratory distress syndrome (ARDS) survivors have significant long-term deterioration in mental, cognitive, and functional health. This study hypothesis is that a specific care program based on early therapeutic education and psychological intervention improves the quality of life of patients at risk of developing PICS and chronic pain after COVID-19 disease.
Description: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health) ]
Measure: Impact of intervention program on health-related quality of life (VAS) Time: Six months after dischargeDescription: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D / 5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health)]
Measure: Impact of intervention program on health-related quality of life (VAS) Time: Three months after discharge.Description: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]
Measure: Impact of intervention program on health-related quality of life (Index) Time: Three months after dischargeDescription: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]
Measure: Impact of intervention program on health-related quality of life (Index) Time: Six months after dischargeDescription: Chronic pain intensity defined by BPI questionnaire (short version), at three and six months after discharge. [Brief pain inventory; A multidimensional questionnaire that evaluates pain intensity in the last 24 hours (worst, lowest, average) and current (right now). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the average intensity score (BPI intensity score) is calculated.]
Measure: Impact of intervention program on chronic pain (intensity) Time: Three and six months after discharge.Description: Limitation of daily activities due to chronic pain, defined by BPI (short version), at three and six months after discharge. [Brief pain inventory; Multidimensional questionnaire that assesses the impact of pain on daily activities (general activity, encouragement, work, relationships with other people, sleep, enjoying life and the ability to walk). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the mean score of the responses related to pain interference in activities (BPI interference score) is calculated.]
Measure: Impact of intervention program on chronic pain (limitation of daily activities) Time: Three and six months after discharge.Description: Pain catastrophization assessed by Pain Catastrophizing Scale at three and six months after hospital discharge. [Pain Catastrophizing Scale; Consisting of 13 questions that explore the frequency of thoughts and feelings that the interviewees have in the presence of current or anticipated pain, which are grouped into three scoring subscales (magnification, rumination and defenselessness). Each question is rated on a 5-point scale (0: not at all; 4: all the time). Being the maximum total score of 52 points.]
Measure: Impact of intervention program on chronic pain (Pain catastrophization) Time: Three and six months after discharge.Description: Clinically significant anxiety or depression symptoms prevalence at three and six months, assessed by the HAD test. [hospital anxiety and depression test; 14 questions, with two subscales, one for anxiety and the other for depression, with seven items each, the maximum score is 21 for each subscale. The cut-off points from zero to seven imply the absence of clinically relevant anxiety and depression, from eight to ten symptoms that require consideration and from 11 to 21 reports the presence of relevant symptoms, with a very probable diagnosis of anxiety or depression.]
Measure: Impact of intervention program on anxiety or depression incidence Time: Three and six months after discharge.Description: Probable post-traumatic stress syndrome prevalence at three and six months after discharge assessed by the DSM ( Diagnostic and Statistical Manual of Mental Disorders) V PTSD Checklist questionnaire (PCL-5) [PTSD Checklist questionnaire; It contains 20 questions that correspond to the DSM V PTSD (Post Traumatic Stress Disorder) criteria. Participants rated their symptoms on a scale of 0 (not at all), 1 (slightly), 2 (moderately), 3 (quite) to 4 (extremely), with a score ranging from 0 to 80. A total of the severity of the symptoms can be made, adding the score of each question (interval 0-80). The severity of each symptom can be evaluated, adding the score of the questions. The cut-off point to use for a provisional diagnosis of PTSD is 31 points.]
Measure: Impact of intervention on probable post-traumatic stress syndrome incidence Time: Three and six months after discharge.As a result of COVID-19 and measures taken by the Canadian Government to reduce the transmission of the virus, in-person psychology services have been suspended. Psychology services are now being conducted via video conferencing. The purpose of the current project is to pilot-test a 6-week Self Compassion Treatment for Chronic Pain delivered virtually, in order to understand its utility in the current environment. The treatment is to be delivered through a secure professional ZOOM licence. Objective 1 of the project is to assess the feasibility and acceptability of attending the treatment group through virtual participation. Objective 2 is to assess the effectiveness of the group treatment in improving self-compassion, mental health, relationship with pain, and quality of life.
Description: Change over time in scores on the Self-Compassion Scale (SCS) (score range is 12-60 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Self-Compassion Scale (SCS) Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Pain Disability Index (score range is 0-70 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Disability Index Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the on the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) (score range is 0-48 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the on the Pain Catastrophizing Scale-6 (PCS-6) (score range is 0-24 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Catastrophizing Scale -6 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 (PSEQ-4) (score range is 0-24 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Numeric Rating Scale (NRS) for pain (score range is 0-10 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Pain Intensity Time: at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Patient Health Questionnaire-9 (PHQ-9) (score range is 0-27 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Generalized Anxiety Scale (GAD-7) (score range is 0-21 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Physical Health and Mental Health Quality of Life scores from the PROMIS GLOBAL-10 (score range is 7-35 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Changes over time in score on the Mindfulness Attention and Awareness Scale (MAAS) (score range is 15-90 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Changes over time in Mindfulness Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Scores on the Client Satisfaction Questionnaire
Measure: Client Satisfaction Time: post treatment (6 weeks after beginning the treatment)Chronic pain is highly prevalent and associated with a large symptom burden, that is had been more concerning during Covid-19 outbreak and lockdown. Benefits of yoga in chronic pain management are very well known. With this background we developed Tele-Yoga therapy program and evaluated the success of this single arm study.
Description: visual-analogic scale (VAS), using pain level from "no pain" (0) to "worst imaginable pain" (10)
Measure: Pain Intensity Time: From baseline to 6-week post interventionDescription: Pain Disability Index (PDI) using seven rating scales, structured in Likert form, from "no disability" (0) to "worst disability" (10)
Measure: Pain Disability Time: From baseline to 6-week post interventionDescription: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring anxiety levels
Measure: Anxiety Time: From Baseline to 6-week post interventionDescription: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring depression levels
Measure: Depression Time: From baseline to 6-week post interventionThis was a prospective observational study with the primary objective of quantifying a change in pain scores after 6-12 months of two separate interventions within the study site (pain team and chiropractic team). Target enrollment was 30 participants for each intervention. The primary outcome was a change from baseline of the Pain Disability Questionnaire (PDQ), the study tool. Secondary outcomes were reduction of opioid dose by morphine equivalent daily dose, and its effect on PDQ scores.
Description: 6-12 month follow up pain score - (minus) baseline. scores range from 0 (no pain or disability) to 150 (severe pain and disability)
Measure: change in Pain Disability Questionnaire (PDQ) score Time: 6-12 monthDescription: ability to successfully wean off opioid prescription
Measure: prescription opioid weaning Time: 6-12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports